Newswire (Published: Tuesday, October 24, 2017, Received: Thursday, October 19, 2017, 7:10:04 PM CDT)

Word Count: 465

Recent Findings from A.C. Gao and Co-Authors Provide New Insights into Prostate Cancer (ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Sacramento, California, by NewsRx journalists, research stated, "Advancements in research have added several new therapies for castration-resistant prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC remains an incurable disease due to the development of therapeutic resistance and the existence of cross-resistance between available therapies."

The news reporters obtained a quote from the research, "Understanding the interplay between different treatments will lead to improved sequencing and the creation of combinations that overcome resistance and prolong survival. Whether there exists cross-resistance between docetaxel and the next-generation taxane cabazitaxel is poorly understood. In this study, we use C4-2B and DU145 derived docetaxel-resistant cell lines to test response to cabazitaxel. Our results demonstrate that docetaxel resistance confers cross-resistance to cabazitaxel. We show that increased ABCB1 expression is responsible for cross-resistance to cabazitaxel and that inhibition of ABCB1 function through the small-molecule inhibitor elacridar resensitizes taxane-resistant cells to treatment. In addition, the anti-androgens bicalutamide and enzalutamide, previously demonstrated to be able to resensitize taxane-resistant cells to docetaxel through inhibition of ABCB1 ATPase activity, are also able to resensitize resistant cells to cabazitaxel treatment. Finally, we show that resensitization using an antiandrogen is far more effective in combination with cabazitaxel than docetaxel. Collectively, these results address key concerns in the field, including that of cross-resistance between taxanes and highlighting a mechanism of cabazitaxel resistance involving ABCB1."

According to the news reporters, the research concluded: "Furthermore, these preclinical studies suggest the potential in using combinations of antiandrogens with cabazitaxel for increased effect in treating advanced CRPC."

For more information on this research see: ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2017;16(10):2257-2266. Molecular Cancer Therapeutics can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research -; Molecular Cancer Therapeutics -

Our news correspondents report that additional information may be obtained by contacting A.C. Gao, VA Northern Calif Hlth Care Syst, Sacramento, CA, United States. Additional authors for this research include C.F. Liu, C.M. Armstrong, V. Cucchiara, X.W. Gu, W. Lou, C.P. Evans and A.P. Lombard (see also Oncology - Prostate Cancer).

Keywords for this news article include: Sacramento, California, United States, North and Central America, Drugs and Therapies, Prostatic Neoplasms, Mitotic Inhibitors, Docetaxel Therapy, Antineoplastics, Pharmaceuticals, Prostate Cancer, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Central America
North America
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Medicinal Drugs